Pfizer Inc. (PFE)
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.
Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude
FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for obesity biotech Metsera (MTSR), valuing it at $10 billion, intensifying the takeover battle.
Pfizer: Market Still Pricing It At Crisis Valuations
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash flows and appealing dividend yield support a bullish view.
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera
Management lowers full-year guidance, warns about competition, launches bid for Metsera.
Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript
Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Pfizer reports strong Q3 earnings, raises full-year profit guidance
Pfizer Inc (NYSE:PFE, ETR:PFE) reported third quarter financial results that topped Wall Street expectations despite a year-over-year drop in earnings and sales, while raising its full-year profit guidance. The company reported Q3 revenue of $16.7 billion, slightly above analyst estimates of $16.55 billion, representing a 7% decline compared with the same period last year.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Pfizer's Q3 Earnings Beat on Top and Bottom Lines
Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected.
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86.20 per share, for a total of around $10 billion.
